Oxford Vaccine Group

What Oxford Vaccine Group does

Oxford Vaccine Group (OVG) is an academic research unit within the Department of Paediatrics at the University of Oxford, founded in 1995 and led by Professor Sir Andrew Pollard. It conducts laboratory and clinical research in infectious diseases and vaccinology, with a translational pipeline spanning antigen design through Phase I-IV clinical trials. Its core technology is the ChAdOx viral vectored vaccine platform, comprising non-replicating chimpanzee adenoviral vectors (ChAdOx1 and ChAdOx2) that deliver genetic instructions for pathogen antigens. The platform was validated at global scale via the Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19), which was authorised in over 180 countries and distributed in excess of 3 billion doses before AstraZeneca's 2024 commercial withdrawal. OVG also operates established Controlled Human Infection Models (CHIM) for typhoid, paratyphoid, pneumococcal (over 1,800 EHPC participants), and other diseases, alongside a broad clinical trial portfolio targeting Ebola BDBV, Marburg, Nipah, Lassa, CCHF, plague, malaria, and typhoid.

OVG's go-to-market is non-commercial: it does not sell products. Vaccines developed in-house are licensed to pharmaceutical partners (historically AstraZeneca, now Serum Institute of India) for manufacturing and global distribution, while OVG retains its role as the originator research group. Direct beneficiaries are clinical trial participants (150,000+ across 30 years), the UK National Health Service and Oxford University Hospitals NHS Foundation Trust (clinical delivery partners), public health authorities such as the WHO and JCVI (policy consumers), and healthcare professionals served through the Vaccine Knowledge Project (9 million page views, 7 million sessions over five years) and the UK Clinical Vaccine Network Conference.

Revenue is grant-based rather than commercial. Funding flows from UKRI, MRC, NIHR, DHSC, the Wellcome Trust, the Bill & Melinda Gates Foundation, CEPI, and WHO, supplemented by named multi-million-pound programme awards (e.g., £1.7M Lymph Node Research UK, June 2026). Sub-brands include the Vaccine Knowledge Project (a WHO Vaccine Safety Net member), the ChAdOx platform, and the Oxford Colloquy podcast hosted by Sir Andrew Pollard. Operational footprint spans three Oxford sites (CCVTM, IDRM, Children's Hospital) plus the Liverpool Vaccine Group at the Liverpool School of Tropical Medicine.

Name

Oxford Vaccine Group

Legal name

Oxford Vaccine Group

Website

https://ovg.ox.ac.uk

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

51–100 employees

Short description

Oxford Vaccine Group is an academic research unit within the University of Oxford's Department of Paediatrics that develops vaccines using the proprietary ChAdOx adenoviral vector platform, runs clinical trials and controlled human infection models for outbreak pathogens, and informs global immunisation policy.

Ownership category

akta.pro rank

Product category

Vaccine Research and Development

NAICS

Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

Keywords

• Vaccine research
• Clinical trials
• Viral vector vaccines
• Infectious disease research
• Human challenge studies

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations

Revenue model

1. Research Grants and Funding: Funded by government agencies, international organizations, and research councils including UKRI, MRC, NIHR, Wellcome Trust, and CEPI for vaccine development research.
2. Clinical Trial Partnerships: Collaborative clinical trials with industry partners such as AstraZeneca for COVID-19 vaccine development and Serum Institute of India for typhoid vaccines.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Oxford Vaccine Group is an academic research unit that develops innovative vaccines against emerging infectious diseases using the proprietary ChAdOx viral vector platform, runs clinical trials (including controlled human infection models) to evaluate vaccine safety and efficacy, and produces evidence-based vaccine information for the public and healthcare professionals. It licenses its vaccine technology to pharmaceutical partners such as AstraZeneca for global manufacturing and distribution, and informs national and international immunisation policy.

Product overview

Oxford Vaccine Group is a research organization within the University of Oxford that develops vaccines and conducts clinical research. Their core technology is the ChAdOx vaccine platform (ChAdOx1 and ChAdOx2), a viral vectored vaccine system using modified chimpanzee adenovirus. They have developed licensed vaccines including the Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19), and have multiple vaccine candidates in development against emerging pathogens (Ebola, Marburg, Lassa, Nipah, CCHF, malaria, typhoid). Beyond vaccine development, they operate the Vaccine Knowledge Project (public health information platform), conduct clinical trials using controlled human infection models, and produce educational content via the Oxford Colloquy podcast. The organization is structured as a clinical research group rather than a commercial product company.

Differentiator

Problem solved

Functional benefit

Brands

• Vaccine Knowledge Project: Independent web platform providing evidence-based information about vaccines and infectious diseases for healthcare professionals and the public globally
• ChAdOx Platform
• The Oxford Colloquy Podcast

Products and services

• ChAdOx Vaccine Platform Viral vectored vaccine platform using modified chimpanzee adenovirus (ChAdOx1 and ChAdOx2) to deliver genetic instructions for pathogen proteins. Licensed to AstraZeneca for COVID-19 vaccine and to Serum Institute of India for outbreak pathogen vaccines. Used across COVID-19, Ebola, Marburg, Lassa, Nipah, CCHF, MERS, plague, and malaria programmes.
• Oxford-AstraZeneca COVID-19 Vaccine (ChAdOx1 nCoV-19) COVID-19 vaccine using the ChAdOx1 adenoviral vector, developed by OVG and licensed to AstraZeneca. Estimated 6.3 million lives saved in the first year of the global vaccine rollout. Used in over 180 countries.
• ChAdOx1 Ebola BDBV Vaccine (BD-Ebov) Vaccine candidate against Bundibugyo ebolavirus developed using ChAdOx1 technology and manufactured with Serum Institute of India for outbreak response.
• ChAdOx1 Marburg Vaccine (MAGIC-01) First-in-human trial of a ChAdOx1 vaccine against Marburg virus, a filovirus in the same family as Ebola.
• ChAdOx1 Nipah Virus Vaccine (NIV001) Phase I trial of a ChAdOx1 vaccine against Nipah virus, a WHO priority pathogen.
• ChAdOx1 Lassa Vaccine (ViTaL-01)

Quantifiable outcome

• 6.3 million lives saved by Oxford-AstraZeneca COVID-19 vaccine in first year
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Nine partnerships are on record, tiered core and major.

• Pandemic Sciences Institute, University of OxfordcoreStrategic or Co-development PartnerCollaborative research institute focused on preventing, preparing for, and responding to pandemic threats; OVG is integral to vaccine development efforts.
• NISEC II (National Immunisation Schedule Evaluation Consortium)coreStrategic or Co-development PartnerCollaboration between Academic Clinical Research groups and UK Health Security Agency to evaluate UK immunisation schedules.
• IMMPROVE ConsortiummajorStrategic or Co-development PartnerConsortium of universities, government, industry and others working to improve vaccine evaluation and development.
• Vaccines and Society UnitmajorStrategic or Co-development PartnerMultidisciplinary research centre studying attitudes and behaviour towards vaccination, helping address vaccine hesitancy.
• Oxford University Hospitals NHS Foundation TrustcoreImplementation/ SI/ Consulting PartnerNHS trust providing clinical infrastructure and consultant appointments for OVG researchers; OVG consultants practice at Oxford Children's Hospital.
• Liverpool School of Tropical MedicinecoreStrategic or Co-development PartnerDaniela Ferreira serves as Director of Liverpool Vaccine Group at LSTM, extending OVG's respiratory infection research with dedicated Accelerator Research Clinic.
• Serum Institute of India Pvt. Ltd. (SIIPL)coreStrategic or Co-development PartnerPartnership to rapidly produce and scale doses of ChAdOx-based monovalent Bundibugyo Ebolavirus candidate vaccine for outbreak response.
• Clinical BioManufacturing Facility, University of OxfordcoreTechnology or IntegrationOxford's own facility for clinical-grade vaccine manufacturing, working with OVG on rapid vaccine production.
• AstraZenecacoreStrategic or Co-development PartnerLicensed Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19/Vaxzevria) for global manufacturing and distribution; over 3 billion doses distributed.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• London School of Hygiene & Tropical Medicine: Major UK academic centre for vaccine epidemiology, clinical trials, and immunisation policy research, with a comparable mix of CHIM-style studies, LMIC field sites, and direct WHO/UK policy engagement.
• NIH Vaccine Research Center: US government intramural vaccine R&D centre that develops and clinically tests novel vaccine platforms (viral vectors, mRNA, protein subunit) against infectious diseases. Closest US analog to OVG's structure and pipeline scope.
• The Pirbright Institute: UK institute focused on viral livestock diseases and zoonotic threats including CCHF, Nipah, and Rift Valley fever, with overlapping target pathogen priorities to OVG's ChAdOx outbreak pipeline.
• Imperial College London Department of Infectious Disease: UK academic group running first-in-human vaccine trials (including its own COVID-19 vaccine) and respiratory/pandemic pathogen research. Closely comparable clinical vaccine R&D mission and faculty pedigree.
• Jenner Institute: University of Oxford-based vaccine R&D institute that co-developed the ChAdOx adenoviral vector platform with OVG and runs parallel early-phase clinical programs in infectious disease vaccines. Direct peer on science, faculty, and pipeline.

Regional players

• MRC Unit The Gambia at LSHTM: West Africa-based MRC/LSHTM research unit running paediatric vaccine trials, CHIM studies, and epidemiologic research. Comparable academic LMIC trial footprint and focus on WHO priority pathogen vaccines.

Broad incumbents

• Wellcome Sanger Institute: Large UK genomic and infectious disease research institute, collaborating with OVG on pathogen genomics and supported by Wellcome Trust. Comparable scale of Wellcome-funded science but broader mandate beyond vaccines.
• GSK Vaccines: Major commercial vaccine developer with a large portfolio across paediatric, travel, and endemic disease vaccines; commercial counterpart and potential licensing partner for OVG-originated candidates.
• Moderna: mRNA vaccine platform company now expanding into outbreak pathogens (Nipah, etc.) where OVG is also active; an emerging competitive pressure on viral vector approaches in the same disease indications.

Others

• Coalition for Epidemic Preparedness Innovations (CEPI): Major funder and coordinator of vaccine development against epidemic threats. Not a research peer but a core partner/funder of OVG's ChAdOx-based outbreak pathogen programs and a key comparator for the ecosystem role OVG plays.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/oxfordvaccgroup
• YouTubeyoutube.com/playlist?list=PLEZupc8yPfsrgc-kRR5Xg8WE7pArl7QKc
• LinkedInlinkedin.com/company/oxford-vaccine-group

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oxford Vaccine Group